Cerenis Therapeutics: Jean-Louis Dasseux

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cerenis Therapeutics: Jean-Louis Dasseux
Released on: September 02, 2010. © PharmaVentures Ltd
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Paul Burge talks with Jean-Louis Dasseux, CEO and President at Cerenis Therapeutics. Filmed at the PharmaTelevision studios in Oxford, UK.
The impact of new HDL Therapies on cardiovascular and metabolic diseases
Paul Burge :
Hello and welcome to PharmaTelevision News Review. On this show today I have Dr. Jean Louis Dasseux , co-founder and CEO of Cerenis Therapeutics a multinational biopharmaceutical company dedicated to the discovery and development of HDL therapies for the treatment of cardiovascular and metabolic diseases. Dr. Jean Louis Dasseux , welcome to Pharma TV News Review, thank you for joining me. Firstly cardiovascular disease the number one cause of mortality and morbidity not only in industrialized nations but emerging counties as well like China, what impact do you think the new HDL therapies will have on these kinds of disease areas?
Jean Louis Dasseux :
So what we know from multiple epidemiological studies is that if you increase your HDL cholesterol levels you will be protected against cardiovascular disease.
Paul Burge :
And could you give me an overview of these new generation of HDL therapies and the types of programs that you are actually working on at the moment?
Jean Louis Dasseux :
Yes, so at Cerenis Therapeutics what we are trying to do is two things, one is to develop products that will in fact will supplement the body by injecting HDL, HDL mimetics. And then the second thing that we are trying to do is to (indiscernable) the small molecules that will push the body to synthesis more HDL.
The phase1 results of niacin combination therapy
Paul Burge :
Okay, now you've had some exciting results recently with a niacin combination therapy in Phase I what of those results been?
Jean Louis Dasseux :
Well what we know for 50-years is that if you administered niacin dose from two to three grams, okay you will be able to push the body to synthesis more HDL and you would be protected against cardiovascular disease, but we also know that niacin induce a lot of side effects in particular flushing meaning redness, scratching, not feeling good and this is a major drawback because 80% of the people taking niacin will stop treatment within a period of one year. What we have tried to achieve with Cerenis Therapeutics new combination between aspirin and niacin is to prevent the flushing.
Development in HDL mimetics
Paul Burge :
Tell me about, tell me more about how HDL mimetics that you currently have in development CER-522 and CER-001 how did they work?
Jean Louis Dasseux :
So what we have tried to do is to mimic the natural HDL, the natural HDL is responsible for what we call the reverse lipid transport pathway meaning that the HDL will go through the vessel wall take cholesterol and bring it to the circulation and then bring it back to the lever where it could be metabolized and eliminated, or recycled, or stored by increasing the HDL concentration we are promoting the reverse lipid transport pathway and therefore potentially remove the atherosclerotic plaque.
Achievement of success in cardiovascular therapies
Paul Burge :
The market for cardiovascular therapies has been validated around $34 billion a year and in the past a number of big pharma have been interested in HDL, but have had problems manufacturing those kinds of compounds, but you"ve succeeded in that area and how you have managed to achieve that?
Jean Louis Dasseux :
That is correct, in fact looking the past for the last 30-years people have tried to produce apolipoprotein-A1 which is the major protein of HDL in bacteria essentially E. coli, unfortunately E. coli is a Gram Negative bacteria producing endotoxin and apolipoprotein-A1 has a higher infinity with other toxin. Therefore it was very difficult to purify the protein meaning multiple steps of purifications and therefore the overall yield of purification was going down and the overall cost was going up meaning that the product was not commercially viable. What we have done at Cerenis Therapeutics is instead of starting to improve the process we have studied from scratch trying to produce the apolipoprotein-A1 in mammalian cell and the cell also creating Apo-A1 in the supernatant facilitating the purification, in fact today in three steps of chromatography we were able to have a highly pure Apo-A1.
Future plans
Paul Burge :
Okay, and as well as overcoming issues with manufacturing how else will Cerenis Therapeutics continue to succeed in other in these areas where others have failed in the past?
Jean Louis Dasseux :
Well at Cerenis Therapeutics we have a group of very talented people that have been working in the field of cardiovascular disease for more than 25-years, have produced multiple prototypes of HDL in the past and we are well funded company, in fact by overcoming the manufacturing process developing validated GMP Process for the production of Apo-A1 as well as the HDL, we feel that we have now achieved a very good quality product that was demonstrated in our Phase I clinical trial, we have filed multiple patents covering this program and therefore we feel that we will be in a position to provide the first and best in class product for HDL therapy, but also we have tried to develop several products using multiple mechanism of action in order to provide patients in need for new therapy for treatment of cardiovascular disease.
Paul Burge :
Okay. Dr. Jean Louis Dasseux , thank you very much indeed for joining me.
Jean Louis Dasseux :
Thank you, and you are welcome.
Paul Burge
Paul Burge is TV Reporter/Video Journalist at BBC News and Freelance Producer/Presenter at PharmaTelevision Ltd. His previous positions include TV Reporter/Video Journalist at Bloomberg News, Reporter/Video Journalist at Agence France Presse, TV Correspondent at Feature Story News, Journalist at ITV and Reporter at NPR.
Jean Louis Dasseux
Tax Partner
Jean Louis Dasseux A co-founder of Cerenis Therapeutics and is one of the world's leading experts in lipid metabolism and lipid-protein interaction. He was the inventor of a high-capacity reverse lipid transport peptide (ETC 642) and a series of small molecule compounds that raise HDL levels. Dr. Jean Louis Dasseux was formerly Vice President of Chemistry and Technology at Esperion Therapeutics. Before joining Esperion, he was Director of Research for the French pharmaceutical company Fournier, where he established and managed its research center in Heidelberg, Germany.
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. PharmaTelevision (PTV) is the groundbreaking online TV channel for the biopharma industry, offering insights and feature interviews with industry leaders every week. Since May 2006, PharmaTelevision has rapidly grown and the channel now boasts a global audience of 5000 industry executives, 60% of whom are C-suite. In 2008, the channel launched a sleek new look and introduced two exciting TV programmes the Financial Report and the Regional Report, which, together with our well-established TV programmes, help to give our viewers a complete overview of industry trends, analysis including deals, investments and strategic policies within the sector.
Cerenis Therapeutics
Cerenis Therapeutics is a multinational biopharmaceutical company, dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Cerenis Therapeutics aims to become the leader in the HDL therapeutic market with a broad portfolio of programs in development.